Hubbry Logo
ZymogenZymogenMain
Open search
Zymogen
Community hub
Zymogen
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Zymogen
Zymogen
Zymogen
View on Wikipedia
from Wikipedia

In biochemistry, a zymogen (/ˈzaɪmədʒən, -moʊ-/[1][2]), also called a proenzyme (/ˌproʊˈɛnzaɪm/[3][4]), is an inactive precursor of an enzyme. A zymogen requires a biochemical change (such as a hydrolysis reaction revealing the active site, or changing the configuration to reveal the active site) to become an active enzyme. The biochemical change usually occurs in Golgi bodies, where a specific part of the precursor enzyme is cleaved in order to activate it. The inactivating piece which is cleaved off can be a peptide unit, or can be independently-folding domains comprising more than 100 residues. Although they limit the enzyme's ability, these N-terminal extensions of the enzyme or a "prosegment" often aid in the stabilization and folding of the enzyme they inhibit.[citation needed]

The pancreas secretes zymogens partly to prevent the enzymes from digesting proteins in the cells where they are synthesised. Enzymes like pepsin are created in the form of pepsinogen, an inactive zymogen. Pepsinogen is activated when chief cells release it into the gastric acid, whose hydrochloric acid partially activates it.[5] Another partially inactivated pepsinogen completes the activation by removing a peptide, turning the pepsinogen into pepsin. Accidental activation of zymogens can happen when the secretion duct in the pancreas is blocked by a gallstone, resulting in acute pancreatitis.[citation needed]

Fungi also secrete digestive enzymes into the environment as zymogens. The external environment has a different pH than inside the fungal cell and this changes the zymogen's structure into an active enzyme.[citation needed]

Another way that enzymes can exist in inactive forms and later be converted to active forms is by activating only when a cofactor, called a coenzyme, is bound. In this system, the inactive form (the apoenzyme) becomes the active form (the holoenzyme) when the coenzyme binds.

In the duodenum, the pancreatic zymogens, trypsinogen, chymotrypsinogen, proelastase and procarboxypeptidase, are converted into active enzymes by enteropeptidase and trypsin. Chymotrypsinogen, a single polypeptide chain of 245 amino acid residues, is converted to alpha-chymotrypsin, which has three polypeptide chains linked by two of the five disulfide bonds present in the primary structure of chymotrypsinogen.[6]

Examples

[edit]

Examples of zymogens:

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Zymogen

View on Grokipedia
from Grokipedia
A zymogen, also known as a proenzyme, is an inactive precursor of an that requires specific biochemical modifications, typically proteolytic cleavage, to become catalytically . This activation process often involves the removal of a propeptide or activation segment that sterically hinders the enzyme's in its zymogenic form. Zymogens are predominantly found among proteolytic enzymes and serve critical regulatory functions by preventing premature or uncontrolled enzymatic activity, which could lead to cellular damage or pathological conditions such as autodigestion in the or unwanted in . In biological systems, they enable precise spatial and temporal control of ; for instance, in the digestive tract, pancreatic zymogens like and are secreted into the and activated sequentially by enterokinase and , respectively, to facilitate protein breakdown without harming pancreatic tissue. Similarly, in , coagulation factors such as prothrombin (factor II zymogen) and zymogen are activated through cascade amplifications to form and factor XIa, essential for clot formation. Other notable examples include , which activates to in the acidic environment for initial protein digestion, and plasminogen, converted to for to dissolve clots. The structural basis of zymogen activation typically involves conformational changes upon cleavage, where the prosegment—ranging from a few to over 100 residues—not only inhibits activity but also aids in proper folding, stability, and intracellular trafficking during . Dysregulation of zymogen activation is implicated in diseases like , where intracellular premature activation of pancreatic zymogens triggers , and certain thrombotic disorders due to aberrant zymogen processing. Overall, zymogens exemplify a sophisticated post-translational regulatory mechanism that balances enzymatic potential with biological safety.

Definition and Characteristics

Definition

A zymogen, also known as a proenzyme, is an inactive precursor of an that requires a specific biochemical change, such as or proteolytic cleavage, to become catalytically active. This form ensures that the enzyme remains dormant until the appropriate conditions or signals trigger its activation. Zymogens are synthesized in cells and stored in an inactive state to prevent unwanted enzymatic activity, which could otherwise lead to cellular damage or uncontrolled . This strategy allows for precise spatial and temporal regulation of enzyme function within the organism. Unlike zymogens, apoenzymes are inactive due to the absence of a required cofactor or coenzyme, rather than needing a structural alteration to achieve activity; the apoenzyme forms the protein backbone of the holoenzyme upon cofactor binding.

Structural Properties

Zymogens are typically synthesized as larger precursors compared to their active enzyme counterparts, owing to the presence of an N-terminal propeptide or activation segment that ranges from a few amino acids to over 100 residues in length. This additional polypeptide chain maintains the enzyme in an inactive state by sterically blocking the active site or enforcing an inhibitory conformation. In serine proteases, such as chymotrypsinogen and trypsinogen, the propeptide serves both as an intramolecular chaperone during folding and as a structural element that prevents premature substrate binding. The molecular architecture of zymogens features a compact, often disordered or flexible structure that differs markedly from the more rigid, ordered conformation of the active . In many cases, the is buried or distorted, with key catalytic elements like the oxyanion hole improperly formed due to misaligned residues, such as the carbonyl group of glycine 193 in profactor D. For instance, in the zymogen form of complement factor D, loops surrounding the S1 specificity are flexible and obstruct access, while the remains intact but non-functional owing to this conformational restraint. These inhibitory domains or peptides ensure latency by distorting the geometry, thereby inhibiting until proteolytic removal of the prosegment, which allows the of the mature to insert into the structure and stabilize the active conformation. Zymogens of secretory enzymes, particularly those from pancreatic acinar cells, are synthesized on ribosomes and translocated into the (ER), where they undergo folding and before being transported through the Golgi apparatus. Within the trans-Golgi network, these proenzymes are selectively sorted and concentrated into immature secretory vesicles that mature into zymogen granules, specialized storage organelles characterized by their dense protein content and acid-resistant membranes. This packaging in zymogen granules facilitates regulated , preventing intracellular and ensuring delivery to extracellular sites where controlled conversion to active enzymes can occur.

History

Origin of the Concept

The term "zymogen" originated in German scientific literature in 1875, coined by physiologist Rudolf Heidenhain to describe an inactive precursor substance that generates an or ferment under specific conditions. Heidenhain derived the word from "Zyme," meaning ferment (from the Greek zyme, referring to leavening or processes), and "-gen," indicating a producer or generator, thus encapsulating the idea of a pro-ferment entity. This emerged amid 19th-century investigations into and , where researchers distinguished between active ferments and their latent forms to explain why glandular extracts often lacked immediate enzymatic activity. Heidenhain introduced the concept in his seminal paper on pancreatic , observing that fresh pancreatic tissue and secretions contained no detectable proteolytic activity, suggesting the presence of an inert mother substance—zymogen—that required activation to yield the functional . These findings built on broader studies dating back to the , when identified as a non-cellular ferment in gastric juice, prompting inquiries into how such agents were stored and mobilized without self-digestion in living tissues. By the mid-1870s, similar inert forms were noted in gastric secretions, where acidic conditions were seen to convert precursors into active ferments, linking zymogen to regulatory mechanisms in digestive . The term entered English scientific discourse around 1877 through the work of British physiologist Michael Foster, who adopted "zymogen" in his Textbook of Physiology to denote these inactive progenitors, facilitating its integration into Anglophone research on glandular function. Foster's usage emphasized the zymogen's role in preventing premature activation during storage in cells like those of the and , a concept that would later inform studies on secretory activation, such as Ivan Pavlov's experiments on conditioned reflexes and enzyme release.

Key Discoveries

The discovery of in 1836 by marked a pivotal advancement in understanding gastric digestion, as he isolated the from extracts and demonstrated its role in protein breakdown under acidic conditions. This finding laid the groundwork for recognizing inactive precursors in digestive processes, though the zymogen form, pepsinogen, was not immediately identified. In 1875, Swedish physiologist Olof Hammarsten provided experimental evidence for pepsinogen as the inactive precursor to through acidification studies on gastric s, showing that the zymogen could be converted to active upon exposure to low pH, thus preventing premature autodigestion in the . Hammarsten's work emphasized the regulatory importance of zymogens in , influencing subsequent on proteolytic . During the 1890s, Russian physiologist advanced zymogen research through his studies on pancreatic enzyme activation, particularly identifying enterokinase (also known as ) in intestinal secretions as the activator of to . 's experiments, utilizing surgical fistulas in dogs, demonstrated the sequential activation of zymogens in the digestive tract, earning him the 1904 in or for his contributions to digestive physiology. In the early , investigations into pancreatic zymogens progressed significantly with the isolation and crystallization of precursors. In 1934, Moses Kunitz and John H. Northrop achieved the crystallization of from bovine pancreas, confirming its proteinaceous nature and enabling detailed studies of its conversion to active via enterokinase cleavage. This breakthrough solidified the zymogen model for pancreatic proteases and facilitated biochemical analyses of activation mechanisms.

Activation Mechanisms

Proteolytic Cleavage

Proteolytic cleavage represents the primary mechanism for activating zymogens, particularly those of serine proteases, through a known as limited proteolysis. In this , a specific within the zymogen is hydrolyzed by an upstream protease, resulting in the removal of an inhibitory prosegment, often an N-terminal extension. This cleavage exposes or reshapes the , transforming the inactive precursor into a catalytically competent . For instance, the cleavage typically occurs at a precise location relative to the , enhancing the enzyme's substrate-binding capability and overall activity by orders of magnitude, often exceeding 1000-fold. The induced by proteolytic cleavage is irreversible, as the of the is an without known biological mechanisms for reversal. This one-way conversion ensures precise temporal and spatial control in enzymatic regulation, preventing premature activity and allowing for committed physiological responses once initiated. In the zymogen form, the catalytic machinery is largely preformed but maintained in a distorted, inactive conformation by the prosegment; cleavage relieves this inhibition, enabling proper alignment of key residues in the . A hallmark of proteolytic zymogen activation is its role in cascade amplification, where the newly formed active cleaves additional zymogens in a sequential manner, exponentially increasing the number of active enzymes. This amplification is evident in systems such as the pancreatic digestive cascade, where initiates the process by cleaving to , which then activates other zymogens like and procarboxypeptidase, potentially generating millions of active molecules from a single initiating event. The specificity of these cleavages is governed by the complementary interactions between the activating protease's and the zymogen's cleavage site, which in zymogens is frequently located after basic residues such as or .

Alternative Activation

While proteolytic cleavage represents the dominant mechanism for zymogen activation, alternative non-proteolytic pathways exist that enable rapid responses in specific physiological or environmental contexts, such as extracellular or microbial settings. pH-dependent activation occurs through conformational rearrangements that expose the without . In aspartic zymogens like pepsinogen, a drop in pH to approximately 2.0 protonates carboxylate groups in the prosegment, destabilizing its interactions with the enzyme core and unfolding the inhibitory region to reveal the catalytic aspartates. Similarly, engineered mutants of prochymosin demonstrate full catalytic activity at pH 2.0 via prosegment dissociation and structural shifts, bypassing cleavage entirely. For procaspase-3, acidification below pH 5 induces dimer dissociation into monomers and increases active-site loop flexibility, conferring partial enzymatic function without . Cofactor binding can also induce zymogen-like precursors into active states by stabilizing productive conformations. Staphylocoagulase, secreted by , binds prothrombin and allosterically reorganizes its —forming the and hole—yielding thrombin-like activity without cleavage. In analogous systems, metal ions such as calcium promote a substrate-competent form of by bridging structural elements in the activation domain. Other triggers, including post-translational modifications and auto-induced changes, further diversify non-proteolytic activation in niche systems. modulates zymogen maturation in serine proteases like TMPRSS13, where N-linked glycans influence trafficking and conformational readiness for activity without altering the cleavage requirement in some variants. In fungal contexts, carboxypeptidase Y undergoes autoactivation via propeptide release through - or ligand-driven conformational shifts, serving as an intracellular chaperone that disengages without . These mechanisms, though rarer than , facilitate swift, reversible control in dynamic environments like microbial infections or acidic compartments.

Biological Importance

Regulatory Functions

Zymogens serve a critical regulatory role by preventing autodigestion within the cells that produce them. Proteolytic enzymes, if active during synthesis or storage, could degrade cellular components, leading to damage or of the producing cells. To mitigate this , these enzymes are synthesized and stored in an inactive zymogenic form within protective granules, such as the zymogen granules in pancreatic acinar cells, which sequester proteases like away from vulnerable cellular structures. This compartmentalization ensures that activation occurs only under controlled conditions, safeguarding the integrity of tissues like the from premature enzymatic activity. Beyond cellular protection, zymogens facilitate precise spatial and temporal control of , restricting proteolytic activity to specific locations and times. For instance, digestive zymogens such as pepsinogen are activated in the acidic environment of the , while pancreatic zymogens like are cleaved in the alkaline milieu of the , ensuring that digestion targets ingested food rather than host tissues. This targeted is achieved through mechanisms like proteolytic cleavage by upstream enzymes or environmental cues, allowing enzymes to function only at intended sites, such as injury locations for hemostatic processes. The zymogenic strategy also enhances biosynthetic efficiency by producing enzymes as single-chain precursors, which simplifies folding and transport compared to assembling multi-subunit active forms. Prosegments in zymogens often assist in proper , stability, and intracellular trafficking, reducing the energetic cost of synthesis and minimizing misfolding risks. Additionally, this approach supports potential feedback , where active s can be rapidly inactivated post-function to prevent prolonged activity and maintain , often through endogenous inhibitors. Such mechanisms ensure that enzyme levels are tightly controlled, integrating zymogen activation into broader regulatory cascades without excessive accumulation.

Role in Physiological Cascades

Zymogen activation operates through sequential cascades where an initial stimulus triggers the conversion of an inactive precursor into an active enzyme, which in turn activates multiple downstream zymogens, thereby amplifying the physiological signal exponentially. This cascade principle allows a single activating event to generate a robust response, enabling rapid and efficient execution of complex biological processes. The proteolytic nature of zymogen activation imparts irreversibility to the process, committing the system to full engagement once initiated and preventing reversal that could compromise critical functions such as tissue repair or defense mechanisms. This one-way progression ensures decisive action in response to stimuli, contrasting with reversible regulatory mechanisms and providing a safeguard against premature or unwarranted activity. To maintain balance within these cascades, zymogens integrate with inhibitory systems, such as serpins and , which form irreversible complexes with activated proteases to halt overamplification and localize the response. These inhibitors act as checkpoints, fine-tuning the cascade's intensity and duration to avoid pathological outcomes like excessive or . Evolutionarily, the modular architecture of zymogen cascades offers significant advantages, permitting the incremental addition of regulatory components that enable precise in multicellular organisms. This flexibility has facilitated the diversification of physiological pathways, enhancing organismal complexity and responsiveness to environmental challenges.

Examples

Digestive Zymogens

Digestive zymogens are inactive precursors of proteolytic enzymes crucial for protein breakdown in the gastrointestinal tract, ensuring controlled activation at specific sites to prevent tissue damage. A primary example is pepsinogen, secreted by chief cells in the gastric mucosa as a proenzyme. In the acidic environment of the stomach, hydrochloric acid (HCl) at approximately pH 2 catalyzes the autocatalytic cleavage of pepsinogen, removing a 44-residue activation peptide to yield the active enzyme pepsin. Pepsin initiates protein digestion by hydrolyzing peptide bonds, preferentially at aromatic amino acid residues, producing smaller peptides that are further processed downstream. In the , pancreatic zymogens play a central role in completing . , synthesized and stored in pancreatic acinar cells, is released into the via the . There, (also known as enterokinase) specifically cleaves the Lys-Ile bond after the activation peptide of , generating active . This initiates a proteolytic cascade: subsequently activates other pancreatic zymogens, including to , proelastase to , and procarboxypeptidase to carboxypeptidase A and B, enabling comprehensive degradation of dietary proteins into and small peptides for absorption. Chymotrypsinogen exemplifies the structural changes underlying zymogen activation. It consists of a single polypeptide of 245 , synthesized in pancreatic acinar cells and maintained in an inactive conformation. Activation by involves sequential cleavages: first at Arg15-Ile16 to form π-chymotrypsin, followed by additional cuts at Leu13-Ser14 and Tyr146-Thr147, resulting in a three- (A : residues 1-13; B : 16-146; C : 149-245) stabilized by five bonds. This rearrangement exposes the , allowing α-chymotrypsin to cleave bonds after large hydrophobic residues like and . Premature intracellular activation of these pancreatic zymogens, particularly to , disrupts the safeguards against autodigestion and can trigger . A common involves gallstones obstructing the , leading to reflux of acids or increased pressure that promotes zymogen conversion within acinar cells, initiating and tissue injury.30377-4/fulltext)

Coagulation Zymogens

Coagulation zymogens are inactive precursors of serine proteases and other enzymes critical to the clotting cascade, ensuring only occurs in response to vascular injury. These zymogens, primarily factors II, VII, IX, X, XI, and XII, undergo sequential proteolytic activation to amplify the clotting signal, culminating in clot formation. Unlike digestive zymogens, which function in the , coagulation zymogens circulate in plasma and are activated at sites of endothelial damage. This regulated activation prevents spontaneous while enabling rapid response to . Prothrombin, or factor II, is a key zymogen in the common pathway of , serving as the precursor to (factor IIa). It is activated by factor Xa in complex with factor Va, calcium ions, and phospholipids on platelet surfaces, forming the prothrombinase complex that cleaves prothrombin at specific residues to generate . is central to formation, as it proteolytically converts soluble fibrinogen into insoluble monomers that polymerize into a clot stabilizing meshwork. Factors VII, IX, X, XI, and XII are serine protease zymogens integral to the extrinsic and intrinsic pathways of coagulation. Factor VII zymogen is activated by exposure during injury in the extrinsic pathway, forming the tissue factor-VIIa complex that initiates downstream activations. Factors IX and X are zymogens activated by this complex or by upstream intrinsic pathway proteases, with factor Xa bridging both pathways to converge on prothrombin activation. Factors XI and XII function in the intrinsic pathway; factor XII auto-activates upon contact with negatively charged surfaces like exposed , subsequently activating , which in turn activates . This sequential zymogen activation amplifies the clotting cascade, producing thrombin bursts far exceeding initial triggers. Factor XIII exists as a zymogen heterotetramer (A2B2) and functions as a precursor rather than a . It is activated by cleavage of its activation peptide in the presence of calcium ions, enabling it to fibrin chains and incorporate alpha-2-antiplasmin, thereby stabilizing the clot against and mechanical stress. This post-fibrin step ensures clot durability without contributing to the initial proteolytic cascade. Vitamin K plays an essential role in the gamma-carboxylation of zymogens such as factors II, VII, IX, and X, modifying residues to gamma-carboxyglutamic acid (). This creates calcium-binding sites in the domains, facilitating membrane association and cofactor interactions necessary for efficient activation and activity in the cascade. Deficiency in impairs , leading to reduced calcium binding and hemorrhagic disorders.

Other Examples

Plasminogen serves as a key zymogen in the fibrinolytic system, synthesized in the liver and circulating in plasma at concentrations of approximately 200 μg/mL. It is activated to the primarily through cleavage of an Arg-Val bond by plasminogen activators such as (tPA) or urokinase-type plasminogen activator (uPA), a process enhanced up to 500-fold when plasminogen binds to surfaces. then degrades clots into soluble fragments, preventing excessive and maintaining vascular patency, with its activity tightly regulated by inhibitors like α₂-antiplasmin to balance . In the complement system, zymogens such as C1r and C1s initiate the classical pathway upon binding of the C1q subunit to antibody-antigen complexes or surfaces, leading to autocatalytic activation of C1r followed by cleavage and activation of C1s. This forms the (C4b2a) after C1s cleaves C4 and C2, amplifying the cascade. C3, the central zymogen at plasma levels of about 1.2 mg/mL, is then cleaved by this convertase into C3a (an anaphylatoxin promoting inflammation) and C3b (an that coats for and forms the membrane attack complex for ). These activations occur across classical, lectin, and alternative pathways, enabling rapid innate immune responses against infections. Fungal aspartyl proteases, such as those in Aspergillus ochraceus and Candida albicans, are secreted as inactive zymogens to prevent premature activity during transit through the secretory pathway. Activation occurs autocatalytically at acidic external pH values below 4.5, where protonation disrupts inhibitory prodomain interactions, enabling dimerization and conformational changes for enzymatic function with optima around pH 2.7–4.3. These proteases degrade host or environmental proteins, facilitating nutrient acquisition like nitrogen from complex sources, which is critical for fungal growth, virulence, and survival in nutrient-limited niches such as infected tissues. In developmental processes, procollagen peptidases like bone morphogenetic protein 1 () and tolloid-like metalloproteinases (mTLL1/2) are produced as zymogens in the trans-Golgi network, featuring inhibitory prodomains that maintain latency until proteolytic removal by subtilisin-like proprotein convertases such as . These enzymes process fibrillar procollagens I–III by cleaving N- and C-terminal propeptides extracellularly, allowing collagen fibril assembly essential for formation in tissue , including skeletal development and . Similarly, ADAMTS2, ADAMTS3, and ADAMTS14 act as tissue-specific N-propeptidases for procollagens I, II, and III, ensuring proper fibril deposition during embryogenesis, with deficiencies linked to disorders like Ehlers-Danlos type VIIC.

References

  1. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/zymogen
  2. https://pubmed.ncbi.nlm.nih.gov/9568890/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC2830560/
  4. https://www.ncbi.nlm.nih.gov/books/NBK482253/
  5. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/zymogen
  6. https://www.biologyonline.com/dictionary/zymogen
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC2143990/
  8. https://www.sciencedirect.com/topics/medicine-and-dentistry/enzyme-precursor
  9. https://pubs.acs.org/doi/10.1021/bi990764v
  10. https://www.embopress.org/doi/10.1093/emboj/18.4.804
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC3329151/
  12. https://wehd.com/105/Zymogen.html
  13. https://www.oed.com/dictionary/zymogen_n
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC5231891/
  15. https://www.journals.uchicago.edu/doi/10.1086/340729
  16. https://www.britannica.com/biography/Michael-Foster
  17. https://www.nobelprize.org/prizes/medicine/1904/pavlov/lecture/
  18. https://www.science.org/doi/10.1126/science.80.2083.505
  19. https://www.pnas.org/doi/pdf/10.1073/pnas.73.11.3825
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC10191478/
  21. https://www.sciencedirect.com/science/article/pii/S0021925821010309
  22. https://www.pnas.org/doi/10.1073/pnas.96.20.10968
  23. https://doi.org/10.1016/S0021-9258(18)66713-4
  24. https://doi.org/10.1110/ps.041003305
  25. https://doi.org/10.1073/pnas.88.20.9330
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC3701954/
  27. https://www.ncbi.nlm.nih.gov/books/NBK537005/
  28. https://pubmed.ncbi.nlm.nih.gov/7828434/
  29. https://biochem.slu.edu/faculty/dicera_new/dicera_files/tibs02_krem.pdf
  30. https://pubmed.ncbi.nlm.nih.gov/1069267/
  31. https://genomebiology.biomedcentral.com/articles/10.1186/gb-2006-7-5-216
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC9110684/
  33. https://www.sciencedirect.com/topics/medicine-and-dentistry/pepsinogen
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC3216344/
  35. https://www.sciencedirect.com/topics/medicine-and-dentistry/trypsinogen
  36. https://www.nature.com/articles/s41467-022-34364-9
  37. https://www.uniprot.org/uniprotkb/P00766/entry
  38. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/chymotrypsin
  39. https://pubs.acs.org/doi/full/10.1021/bi00811a022
  40. https://www.ncbi.nlm.nih.gov/books/NBK482468/
  41. https://hemostasis.bidmc.org/wp-content/uploads/2018/02/Review-of-the-Molecular-Basis-of-Coagulation-Cell-1988.pdf
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC7149769/
  43. https://www.sciencedirect.com/topics/neuroscience/blood-clotting-factor-12
  44. https://ashpublications.org/blood/article/146/12/1412/535293/Factor-XIII-driving-cross-links-in-hemostasis
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC5064719/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC9146348/
  47. https://www.sciencedirect.com/topics/medicine-and-dentistry/vitamin-k-dependent-carboxylase
  48. https://www.ncbi.nlm.nih.gov/books/NBK539745/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC4314363/
  50. https://www.ncbi.nlm.nih.gov/books/NBK27100/
  51. https://www.ncbi.nlm.nih.gov/books/NBK544229/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC11241649/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC11084781/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC2722432/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC4316204/
Add your contribution
Related Hubs
User Avatar
No comments yet.